A Phase 1 interventional study of [¹⁴C]Opevesostat and Prednisone in Metastatic Prostate Cancer, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United Kingdom. Open to male participants aged 30 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-23.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Prostatic Neoplasms by Merck & Co., Inc — 4 open to participants now, 6 under way, 3 of them phase 3. Prostatic Neoplasms · Merck & Co., Inc.
Among the 22 studies in Prostatic Neoplasms by Merck & Co., Inc, this one is the 19th largest by enrollment, is one of 3 that started in 2024, is one of 6 in phase 1, and was the 20th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 22 studies in Prostatic Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 32 more countries
Ages 18+ · Men only
Merck Sharp & Dohme LLC · Sites in United States, Argentina, Australia and 33 more countries
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Australia, Brazil and 36 more countries
Ages 18+
Merck Sharp & Dohme LLC
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 30 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 7 · Phase 3 9
First in 2003; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 93 across the 22 interventional studies. Of the 15 that completed or were terminated, 6 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
1 of the studies in Prostatic Neoplasms by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02861573Merck Sharp & Dohme LLCStudy of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | 2027-10-22 |
Add it to your calendar (.ics) → With an account.
Among the 22 studies in Prostatic Neoplasms by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study of opevesostat in healthy adult male participants. The purpose of this study is to understand the absorption, distribution, metabolism, and elimination of opevesostat in humans, as well as its pharmacokinetics (PK), metabolic profile, and safety and tolerability.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
On Day 1, participants receive a single dose of \[¹⁴C\]opevesostat as an oral solution. Participants then receive single doses of 5.0 mg prednisone and 0.05 mg fludrocortisone tablets 4 hours later as hormone replacement therapy.
Drug: [¹⁴C]Opevesostat · Drug: Prednisone · Drug: Fludrocortisone
Oral solution
Also known as: MK-5684
Tablet
Also known as: RAYOS®, STERAPRED®, DELTASONE®
Tablet
Also known as: FLORINEF®
Cumulative amount of total radioactivity excreted in urine (CumAeu) after administration of single-dose [¹⁴C]Opevesostat
Urine samples will be collected at pre-specified timepoints and used to determine CumAeu.
Time frame: Predose and at designated time points (up to 8 days)
Cumulative amount of total radioactivity excreted in feces (CumAef) after administration of single-dose [¹⁴C]Opevesostat
Fecal samples will be collected at pre-specified timepoints and used to determine CumAef.
Time frame: Predose and at designated time points (up to 8 days)
Cumulative percentage of total radioactivity excreted in urine (Cumfeu) after administration of single-dose [¹⁴C]Opevesostat
Urine samples will be collected at pre-specified timepoints and used to determine CumFeu.
Time frame: Predose and at designated time points (up to 8 days)
Cumulative percentage of total radioactivity excreted in feces (Cumfef) after administration of single-dose [¹⁴C]Opevesostat
Fecal samples will be collected at pre-specified timepoints and used to determine Cumfef.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Opevesostat Pharmacokinetics: Area under the curve from time 0 to the time of last measurable concentration (AUC0-t)
Plasma samples will be collected at pre-specified timepoints and used to determine AUC0-t of opevesostat.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Opevesostat Pharmacokinetics: Area under the curve from time 0 to extrapolated infinity (AUC0-inf)
Plasma samples will be collected at pre-specified timepoints and used to determine AUC0-inf of opevesostat.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Opevesostat Pharmacokinetics: Maximum observed concentration (Cmax)
Plasma samples will be collected at pre-specified timepoints and used to determine Cmax of opevesostat.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Opevesostat Pharmacokinetics: Time of maximum observed concentration (Tmax)
Plasma samples will be collected at pre-specified timepoints and used to determine Tmax of opevesostat.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Opevesostat Pharmacokinetics: Terminal elimination half-life (t1/2)
Plasma samples will be collected at pre-specified timepoints and used to determine t1/2 of opevesostat.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Total Radioactivity Pharmacokinetics: Area under the curve from time 0 to the time of last measurable concentration (AUC0-t)
Plasma samples will be collected at pre-specified timepoints and used to determine AUC0-t of total radioactivity.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Total Radioactivity Pharmacokinetics: Area under the curve from time 0 to extrapolated infinity (AUC0-inf)
Plasma samples will be collected at pre-specified timepoints and used to determine AUC0-inf of total radioactivity.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Total Radioactivity Pharmacokinetics: Maximum observed concentration (Cmax)
Plasma samples will be collected at pre-specified timepoints and used to determine Cmax of total radioactivity.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Total Radioactivity Pharmacokinetics: Time of maximum observed concentration (Tmax)
Plasma samples will be collected at pre-specified timepoints and used to determine Tmax of total radioactivity.
Time frame: Predose and at designated time points (up to 8 days)
Plasma Total Radioactivity Pharmacokinetics: Terminal elimination half-life (t1/2)
Plasma samples will be collected at pre-specified timepoints and used to determine t1/2 of total radioactivity.
Time frame: Predose and at designated time points (up to 8 days)
Total Number of Metabolites in Plasma that Represent at least 10% of the Dose of Radioactivity
Plasma samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.
Time frame: Predose and at designated time points (up to 8 days)
Total Number of Metabolites in Urine that Represent at least 10% of the Dose of Radioactivity
Urine samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.
Time frame: Predose and at designated time points (up to 8 days)
Total Number of Metabolites in Feces that Represent at least 10% of the Dose of Radioactivity
Fecal samples will be collected at pre-specified timepoints and used to determine the total number of metabolites that represent at least 10% of the dose of radioactivity. Metabolites will be determined using liquid scintillation and high-resolution mass spectrometry.
Time frame: Predose and at designated time points (up to 8 days)
Number of Participants with One or More Adverse Events (AEs)
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants who experienced an AE will be reported.
Time frame: Up to approximately 8 days
Number of Participants who Discontinue from the Study Due to an AE
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. The number of participants who discontinue from the study due to an AE will be reported.
Time frame: Up to approximately 8 days
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Sep 2024 to primary completion in Oct 2024, 0 months.
Of 212 industry-sponsored phase 1 interventional studies under Prostatic Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's 0 months is below that.
Counting every sponsor, half of 456 studies reached it within 43 months; a quarter within 23 and three quarters within 68.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Opevesostat